Suraksha Diagnostic Limited has informed the Exchange about an Update on the Acquisition

Acquisition announcedStrategic Transactions View source PDF Explain this filing

SURAKSHA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.5%Reaction day

₹270.00

prior close

₹270.89

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+2.4%+0.1% vs market

Healthcare Service Provider peers, median of 22sector+0.3%+2.2% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 2.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+0.4

15m

-0.1

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.5+2.4+0.1+0.3+2.2

Next day

+2.6+1.1+1.5+1.2+1.4

+1.3+4.6-3.3-0.2+1.5

+6.9+7.9-1.1+1.9+4.9

+12.2+8.8+3.4+3.6+8.6

+8.7+9.6-0.9+3.5+5.3

+16.7+12.2+4.4+7.2+9.4

15d

+9.3+8.6+0.6+1.1+8.2

+5.7+6.2-0.5-1.4+7.1

+24.4+22.7+1.7+6.7+17.7

+18.9+23.5-4.6+6.7+12.2

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 22Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suraksha Diagnostic Limited has completed signing of all definitive agreements to acquire a 63% stake in Fetomat Wellness Private Limited for an amount not exceeding ₹5.19 crore in cash. Fetomat is a Kolkata-based network of fertility and pregnancy care clinics specialising in fetal and maternal medicine, with a FY24 turnover of approximately ₹4.11 crore and EBITDA of around ₹0.56 crore. The deal includes subscription for 16.17% via new shares and purchase of 46.83% from existing shareholders, totalling 3,73,423 equity shares. Post-acquisition, Fetomat will become a subsidiary of Suraksha. The payment of consideration and transfer of shares will be communicated in due course, with completion expected within three months from the original 27 March 2025 board approval.

Likely market impact

This is a small-ticket strategic acquisition (₹5.19 crore) that expands Suraksha's service portfolio into fetal medicine and women's health, making Fetomat a subsidiary. The move strengthens its healthcare footprint in eastern India and adds a complementary vertical, though the financial impact is limited given the modest size of the target.